Thomas Kosasa - 19 Jan 2024 Form 4 Insider Report for OneMedNet Corp (ONMD)

Reporting relationship: Director
Issuer ticker: ONMD
Reported as of: 19 Jan 2024
Net transaction value: +$5,244,658
SEC form: 4
Accepted by SEC: 26 Nov 2025, 21:54:50 UTC
Prior SEC filing: 15 Nov 2023
Next SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Golden, Attorney-in-Fact

Key filing fact

Thomas Kosasa filed Form 4 for OneMedNet Corp (ONMD) on 26 Nov 2025.

Key facts

This page summarizes Thomas Kosasa's Form 4 filing for OneMedNet Corp (ONMD).
11 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Nov 2025, 21:54.

Change

Previous filing in this sequence was filed on 15 Nov 2023.
Current net transaction value: +$5,244,658.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001989846 Primary reporting owner

Kosasa Thomas

Relationship: Director
Address: 6385 OLD SHADY OAK ROAD, SUITE 250, EDEN PRAIRIE
Signature: /s/ Robert Golden, Attorney-in-Fact
Signature date: 26 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONMD transaction

Common Stock

Award

Transaction value: $0
Shares: +45,000
Change %: +0.54%
Price: $0.000000
Shares after: 8,378,824
Date: 19 Jan 2024
Ownership: Direct
Footnotes: F1

ONMD transaction

Common Stock

Purchase

Transaction value: $22,861
Shares: +47,000
Change %: +0.56%
Price: $0.4864
Shares after: 8,425,824
Date: 21 Apr 2025
Ownership: Direct

ONMD transaction

Common Stock

Purchase

Transaction value: $21,016
Shares: +55,000
Change %: +0.65%
Price: $0.3821
Shares after: 8,480,824
Date: 16 Jun 2025
Ownership: Direct

ONMD transaction

Common Stock

Conversion of derivative security

Transaction value: $562,084
Shares: +493,056
Change %: +5.8%
Price: $1.14
Shares after: 8,973,880
Date: 17 Jun 2025
Ownership: Direct
Footnotes: F2

ONMD transaction

Common Stock

Conversion of derivative security

Transaction value: $1,598,938
Shares: +2,123,424
Change %: +24%
Price: $0.7530
Shares after: 11,097,304
Date: 19 Jun 2025
Ownership: Direct
Footnotes: F3

ONMD transaction

Common Stock

Conversion of derivative security

Transaction value: $2,034,161
Shares: +2,865,016
Change %: +26%
Price: $0.7100
Shares after: 13,962,320
Date: 19 Jun 2025
Ownership: Direct
Footnotes: F4

ONMD transaction

Common Stock

Purchase

Transaction value: $500,000
Shares: +1,190,476
Change %: +8.5%
Price: $0.4200
Shares after: 15,152,796
Date: 20 Jun 2025
Ownership: Direct
Footnotes: F5

ONMD transaction

Common Stock

Purchase

Transaction value: $500,000
Shares: +581,395
Change %: +3.8%
Price: $0.8600
Shares after: 15,734,191
Date: 29 Aug 2025
Ownership: Direct
Footnotes: F6

ONMD transaction

Common Stock

Purchase

Transaction value: $5,599
Shares: +6,000
Change %: +0.04%
Price: $0.9331
Shares after: 15,740,191
Date: 24 Sep 2025
Ownership: Direct

ONMD transaction

Common Stock

Award

Transaction value: $0
Shares: +45,000
Change %: +0.29%
Price: $0.000000
Shares after: 15,785,191
Date: 26 Nov 2025
Ownership: Direct
Footnotes: F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONMD transaction Derivative

Senior Secured Convertible Note

Conversion of derivative security

Transaction value
Shares: -493,056
Change %: -100%
Price
Shares after: 0
Date: 17 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 493,056
Exercise price: $1.14
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan (the "2022 Plan") for board service in fiscal year 2024. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vested on December 31, 2024.

Footnote F2

On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

Footnote F3

On June 19, 2025, the reporting person delivered notice of his election to convert in full the amounts of outstanding principal under certain convertible shareholder loans previously made by the reporting person to the issuer, in an aggregate principal amount of approximately $1.6 million.

Footnote F4

On June 19, 2025, the issuer entered into an agreement with the reporting person to convert an aggregate of approximately $2.0 million of outstanding principal and accrued interest under certain shareholder loans and business combination extension loans.

Footnote F5

On June 20, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant which the issuer agreed to sell 1,190,476 shares of common stock to the reporting person at a purchase price of $0.42 per share, totaling $500,000 in gross proceeds to the issuer.

Footnote F6

On August 29, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant to which the issuer agreed to sell 581,395 shares of common stock to the reporting person at a purchase price of $0.86 per share, totaling $500,000 in gross proceeds to the issuer.

Footnote F7

Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date.